Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease

Published:2019-11-25 Issue:1 Volume:51 Page:90-109
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Palmer Melissa¹^ORCID,Regev Arie²^ORCID,Lindor Keith³,Avigan Mark I.⁴,Dimick-Santos Lara⁴,Treem William¹,Marcinak John F.⁵,Lewis James H.⁶,Anania Frank A.⁴,Seekins Daniel⁷,Shneider Benjamin L.⁸,Chalasani Naga⁹

Affiliation:

1. Takeda; Cambridge MA USA

2. Eli Lilly and Company; Indianapolis IN USA

3. Mayo Clinic; Phoenix AZ USA

4. US Food and Drug Administration; Silver Spring MD USA

5. Takeda; Deerfield IL USA

6. Georgetown University Hospital; Washington DC USA

7. Bristol-Myers Squibb; Lawrenceville NJ USA

8. Baylor College of Medicine; Houston TX USA

9. Indiana University School of Medicine; Indianapolis IN USA

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15579/fullpdf

Reference170 articles.

1. International Consortium for Innovation & Quality in Pharmaceutical Development DILI (IQ DILI) Iq dili initiative www.iqdili.org

2. Criteria of drug-induced liver disorders. Report of an international consensus meeting;Benichou;J Hepatol,1990

3. Causality assessment of adverse reactions to drugs-ii. An original model for validation of drug causality assessment methods: case reports with positive rechallenge;Benichou;J Clin Epidemiol,1993

4. Case definition and phenotype standardization in drug-induced liver injury;Aithal;Clin Pharmacol Ther,2011

5. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity;Chalasani;Gastroenterology,2004

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver toxicity in oncology trials and beyond: a simplified concept for management of hepatocellular drug-induced liver injury in patients with abnormal baseline liver tests;Expert Opinion on Drug Safety;2024-04-02

2. Drug-induced liver injury in patients with underlying liver disease;Clinical Liver Disease;2024-01

3. Liver and Gall Bladder;Haschek and Rousseaux' s Handbook of Toxicologic Pathology;2024

4. In Vivo and In Silico Studies of the Hepatoprotective Activity of Tert-Butylhydroquinone;International Journal of Molecular Sciences;2023-12-29

5. Modern hepatoprotection: a narrative review of existing approaches and prospects for the use of biotechnological drugs;Modern medical technology;2023-09-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3